A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NYU Langone Health
Dana-Farber Cancer Institute
University of Florida
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University Hospital, Grenoble
Roswell Park Cancer Institute
Gruppo Oncologico del Nord-Ovest
Stanford University
University of Pittsburgh
University of Minnesota
Rutgers, The State University of New Jersey
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Northwestern University
Children's Hospital Medical Center, Cincinnati
Center Eugene Marquis
University Hospital, Bordeaux
ProgenaBiome
Weill Medical College of Cornell University
Fudan University
Cancer Research UK
UNICANCER
Xijing Hospital of Digestive Diseases
Ohio State University Comprehensive Cancer Center
UMC Utrecht
The Clatterbridge Cancer Centre NHS Foundation Trust
Oslo University Hospital
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Zhejiang Cancer Hospital
Universita di Verona
Obafemi Awolowo University Teaching Hospital
Universitätsklinikum Hamburg-Eppendorf
Shanghai Minimally Invasive Surgery Center
The Christie NHS Foundation Trust
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tenwek Hospital
Shenzhen People's Hospital
Midwest Veterans' Biomedical Research Foundation
Guangzhou Women and Children's Medical Center
Zhejiang University
Oslo University Hospital
Beijing Tsinghua Chang Gung Hospital
Kantonsspital Winterthur KSW
Hospital Universitari de Bellvitge
Changhai Hospital
Sun Yat-sen University
The Clatterbridge Cancer Centre NHS Foundation Trust